Nodal Marginal Zone B Cell Lymphoma C0855139
A slow-growing type of non-Hodgkin lymphoma affecting white blood cells in the lymph nodes. It typically occurs in adults and often progresses slowly. Treatment may include watchful waiting or targeted therapies.
Key facts at a glance
- ICD-10
- C88.40, C88.41
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Lymphadenopathy
(hematologic)Cytopenias
(hematologic)B symptoms
(hematologic)Autoimmune hemolytic anemia
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Active Surveillance Protocol
Careful observation with regular imaging and laboratory assessments for asymptomatic patients with indolent disease, avoiding treatment until progression.
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Anti-CD20 Monoclonal Antibody Therapy
Targeted immunotherapy directed against CD20 antigen on B-cells, often used as first-line treatment for this type of B-cell lymphoma.
Additional treatment options
Involved Site Radiation Therapy
Localized radiation treatment for early-stage disease or symptomatic bulky lymph nodes, providing targeted tumor control.
procedureImmunochemotherapy Regimen
Combination of chemotherapy agents with immunotherapy for more advanced or progressive disease requiring systemic treatment.
medicationOncology Psychological Support
Professional mental health support to address cancer diagnosis anxiety, treatment side effects, and survivorship challenges.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Nodal Marginal Zone B Cell Lymphoma C0855139?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019.
Swerdlow SH, Campo E, Harris NL, et al. Marginal Zone Lymphomas. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. Lyon: IARC Press; 2017.
Conconi A, Martinelli G, Thieblemont C, et al. Clinical Activity of Rituximab in Extranodal Marginal Zone B-Cell Lymphoma of MALT Type. Blood. 2003.
Thieblemont C, Davi F, Leclercq D, et al. Optimizing Therapy for Nodal Marginal Zone B-Cell Lymphoma: A Systematic Review. Ann Oncol. 2016.
Medication Comparisons
Compare medications used to treat Nodal Marginal Zone B Cell Lymphoma C0855139. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy